Tourmaline Bio Profit Margin

The latest profit margin for TRML is -221185.0% as of June 2025. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Tourmaline Bio's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, TRML currently prints -221185.0% for profit margin, while the sector average sits near 13.89%. That is roughly 1592152.1% below the sector mean. Large gaps often invite a closer look at Tourmaline Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Tourmaline Bio converts resources into returns. At -221185.0%, TRML may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TRML's profit margin (-221185.0%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Tourmaline Bio's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.